ATE259420T1 - Mutanten des keratinocyten-wachstumsfaktor-2 (kgf-2 oder fibroblastenwachstumsfaktor-12,fgf-12) - Google Patents

Mutanten des keratinocyten-wachstumsfaktor-2 (kgf-2 oder fibroblastenwachstumsfaktor-12,fgf-12)

Info

Publication number
ATE259420T1
ATE259420T1 AT97937200T AT97937200T ATE259420T1 AT E259420 T1 ATE259420 T1 AT E259420T1 AT 97937200 T AT97937200 T AT 97937200T AT 97937200 T AT97937200 T AT 97937200T AT E259420 T1 ATE259420 T1 AT E259420T1
Authority
AT
Austria
Prior art keywords
growth factor
kgf
polynucleotides
polypeptides
fgf
Prior art date
Application number
AT97937200T
Other languages
English (en)
Inventor
Roxanne Duan
Steven M Ruben
Pablo Jimenez
Mark A Rampy
Donna Mendrick
Jun Zhang
Jian Ni
Paul A Moore
Timothy A Coleman
Reiner L Gentz
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26697695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE259420(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of ATE259420T1 publication Critical patent/ATE259420T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
AT97937200T 1996-08-13 1997-08-13 Mutanten des keratinocyten-wachstumsfaktor-2 (kgf-2 oder fibroblastenwachstumsfaktor-12,fgf-12) ATE259420T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2385296P 1996-08-13 1996-08-13
US3904597P 1997-02-28 1997-02-28
PCT/US1997/014112 WO1998006844A1 (en) 1996-08-13 1997-08-13 Keratinocyte growth factor-2 (kgf-2 or fibroblast growth factor-12, kgf-12)

Publications (1)

Publication Number Publication Date
ATE259420T1 true ATE259420T1 (de) 2004-02-15

Family

ID=26697695

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97937200T ATE259420T1 (de) 1996-08-13 1997-08-13 Mutanten des keratinocyten-wachstumsfaktor-2 (kgf-2 oder fibroblastenwachstumsfaktor-12,fgf-12)

Country Status (13)

Country Link
EP (1) EP0950100B1 (de)
JP (1) JP2000517174A (de)
KR (1) KR20000029986A (de)
CN (1) CN1234071A (de)
AT (1) ATE259420T1 (de)
AU (1) AU739773B2 (de)
CA (1) CA2263143A1 (de)
DE (1) DE69727589T2 (de)
DK (1) DK0950100T3 (de)
ES (1) ES2212121T3 (de)
NZ (1) NZ333725A (de)
PT (1) PT950100E (de)
WO (1) WO1998006844A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
EP0751992B1 (de) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
EP1473366A1 (de) * 1996-10-15 2004-11-03 Amgen Inc. Produkte des Keratinocyten-Wachstumsfaktors 2
DK0935652T3 (da) * 1996-10-15 2004-07-26 Amgen Inc Keratinocyt vækstfaktor-2 produkter
AU775027C (en) * 1996-10-15 2005-12-08 Biovitrum Ab (Publ) Keratinocyte growth factor-2 products
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
KR20010033484A (ko) 1997-12-22 2001-04-25 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2 제제
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6599879B1 (en) * 1998-02-13 2003-07-29 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
CA2322748A1 (en) * 1998-03-13 1999-09-16 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP1179064A2 (de) * 1999-05-14 2002-02-13 Curagen Corporation Sekretionspolypeptiden und übereinstimende polynukleotiden
KR20020010920A (ko) * 1999-06-02 2002-02-06 추후제출 각질세포 성장 인자-2 제제
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
EP1357931A2 (de) * 2001-01-08 2003-11-05 Human Genome Sciences, Inc. Keratinozyt-wachstumsfaktor-2
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US8871709B2 (en) * 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
CN107041948A (zh) * 2009-01-21 2017-08-15 北京三有利科技发展有限公司 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用
ES2626327T3 (es) * 2009-02-06 2017-07-24 The Regents Of The University Of California Agentes enlazantes de calcio que inducen crecimiento del cabello y/o crecimiento de las uñas
CN102727890A (zh) * 2012-07-05 2012-10-17 吉林农业大学 抗重组人角质细胞生长因子-2抗体的应用
MX2016005614A (es) 2013-11-01 2016-12-09 Spherium Biomed S L Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
CN104474533A (zh) * 2014-11-24 2015-04-01 华南理工大学 一种可用于创面修复的复合微球的制备方法
CN104593320B (zh) * 2015-01-04 2017-05-17 许永安 一种汗腺分化诱导培养基及其应用
US9597274B2 (en) * 2015-06-17 2017-03-21 Avon Products, Inc. Peptides and their use in the treatment of skin
CN109402130A (zh) * 2018-11-23 2019-03-01 成都中医药大学附属医院 一种重组人角质细胞生长因子-1及其制备方法和用途
CN111588837B (zh) * 2020-05-14 2023-06-06 中南大学湘雅三医院 一种蛋白-纳米银复合物的制备方法及制备的复合物和用途
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도
CN112675294B (zh) * 2021-03-12 2021-05-14 诺赛联合(北京)生物医学科技有限公司 一种成纤维细胞的制备及在整形外科修复中的应用
WO2022204331A1 (en) * 2021-03-24 2022-09-29 Combangio, Inc. Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment
EP4183796A1 (de) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostabiles fgf10-polypeptid oder fragment davon, verwendung davon
CN117736338A (zh) * 2023-12-08 2024-03-22 温州医科大学 一种角质细胞生长因子-透皮肽融合蛋白及其制备与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241639T1 (de) * 1995-02-14 2003-06-15 Human Genome Sciences Inc Keratinozyten-wachstumsfaktor 2
DK0935652T3 (da) * 1996-10-15 2004-07-26 Amgen Inc Keratinocyt vækstfaktor-2 produkter

Also Published As

Publication number Publication date
WO1998006844A1 (en) 1998-02-19
JP2000517174A (ja) 2000-12-26
DE69727589D1 (de) 2004-03-18
ES2212121T3 (es) 2004-07-16
AU739773B2 (en) 2001-10-18
DE69727589T2 (de) 2004-08-05
AU3977097A (en) 1998-03-06
PT950100E (pt) 2004-06-30
DK0950100T3 (da) 2004-06-07
EP0950100B1 (de) 2004-02-11
EP0950100A1 (de) 1999-10-20
KR20000029986A (ko) 2000-05-25
CN1234071A (zh) 1999-11-03
NZ333725A (en) 2000-10-27
CA2263143A1 (en) 1998-02-19

Similar Documents

Publication Publication Date Title
DE69727589D1 (de) Mutanten des KERATINOCYTEN-WACHSTUMSFAKTOR-2 (KGF-2 ODER FIBROBLASTENWACHSTUMSFAKTOR-12,FGF-12)
WO2002077155A3 (en) Keratinocyte growth factor-2
BG107537A (bg) Инхибиране на човешка tnf алфа активност
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
GB8909919D0 (en) Small polypeptides
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
DK0807633T3 (da) Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner
ATE245435T1 (de) Totalsynthese des amino hip analogen von didemnin a
HUT50148A (en) Process for production of derivatives of antiflammation furanon and medical compositions containing them
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE94882T1 (de) Heparinbindende gehirnmitogene.
DE68903907D1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
ZA9010080B (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
GR3017358T3 (en) 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants.
EP0826041A4 (de) Transformierender wachstumsfaktor alpha hii (tg1f & hii)
AU4288285A (en) Novel pharmaceutical compositions having immuno-suppressive properties
ES2061667T3 (es) Agente hipotensivo para el tratamiento o prevencion de la hipertension.
ES2073919T3 (es) Derivados de piperidina 1,3,4-trisubstituidos, su obtencion y empleo.
MY107336A (en) The process for the preparation of enantiomerically pure thienopyran derivatives.
ZA874448B (en) Cis & trans stilbenes and their composition for the treatment of hypertension
GR3024709T3 (en) Novel cytarabine derivatives, their production and use
MX9800686A (es) Nueva proteina hmw humana mp52s.
NZ337632A (en) Method for inhibiting human vascular IBF-like growth factor (VIGF) comprising a VIGF polypeptide or polypeptide having the cDNA contained in ATCC 75874

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0950100

Country of ref document: EP

RZN Patent revoked